Tag: Individualized Drug Safety

By Posted on Posted in Adverse Drug Reaction [ADR], Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics, Thasso Post, Theragenomic Medicine, Theragenomics, Theragenomics of Individualized Drug Safety Tagged with , , , , , , , , , , , , , , , , , , , ,

December 28, 2020 – Some 95% of people have gene variants that may negatively affect their response to at least one drug, leading to unexpected or adverse drug reactions (ADRs) or, if unlucky, to a serious, if not fatal, adverse …

Genetics behind some serious adverse drug reactions (SADRs) Read more »

By Posted on Posted in Allelic Variant, Companion Test, Diagnostic, Genetic Background, Genetic Predisposition, Genetic Susceptibility, On The Horizon, Personalized Medicine, Pharmacogenetics, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with , , , , , , ,

July 9, 2016 – This is a huge step into the future of theragenomic and personalized medicine and individualized drug safety. In support of the President’s Precision Medicine Initiative (PMI), the American Food & Drug Administration (FDA) just issued two …

Precision Medicine Initiative: draft guidances issued Read more »